254 related articles for article (PubMed ID: 18074761)
1. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
Grossarth-Maticek R; Ziegler R
Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
[TBL] [Abstract][Full Text] [Related]
2. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
[TBL] [Abstract][Full Text] [Related]
3. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
[TBL] [Abstract][Full Text] [Related]
4. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
[TBL] [Abstract][Full Text] [Related]
5. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2007 Jun; 14(3):140-7. PubMed ID: 17596694
[TBL] [Abstract][Full Text] [Related]
6. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
7. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador).
Ziegler R; Grossarth-Maticek R
Evid Based Complement Alternat Med; 2010 Jun; 7(2):157-66. PubMed ID: 18955332
[TBL] [Abstract][Full Text] [Related]
8. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
11. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review.
Ostermann T; Raak C; Büssing A
BMC Cancer; 2009 Dec; 9():451. PubMed ID: 20021637
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings.
Ostermann T; Appelbaum S; Poier D; Boehm K; Raak C; Büssing A
Complement Med Res; 2020; 27(4):260-271. PubMed ID: 31927541
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro.
Eggenschwiler J; Patrignani A; Wagner U; Rehrauer H; Schlapbach R; Rist L; Ramos MH; Viviani A
Arzneimittelforschung; 2006 Jun; 56(6A):483-96. PubMed ID: 16927530
[TBL] [Abstract][Full Text] [Related]
14. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
[TBL] [Abstract][Full Text] [Related]
15. Anticarcinogenic and antimetastatic activity of Iscador.
Kuttan G; Menon LG; Antony S; Kuttan R
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S15-6. PubMed ID: 9179361
[TBL] [Abstract][Full Text] [Related]
16. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Büssing A
Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532
[TBL] [Abstract][Full Text] [Related]
17. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro.
Kelter G; Fiebig HH
Arzneimittelforschung; 2006 Jun; 56(6A):435-40. PubMed ID: 16927523
[TBL] [Abstract][Full Text] [Related]
18. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador.
Urech K; Schaller G; Jäggy C
Arzneimittelforschung; 2006 Jun; 56(6A):428-34. PubMed ID: 16927522
[TBL] [Abstract][Full Text] [Related]
19. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
Matthes H; Friedel WE; Bock PR; Zänker KS
Curr Mol Med; 2010 Jun; 10(4):430-9. PubMed ID: 20455850
[TBL] [Abstract][Full Text] [Related]
20. [What prospects of success does Iscador therapy offer in advanced ovarian cancer?].
Hassauer W; Gutsch J; Burkhardt R
Onkologie; 1979 Feb; 2(1):28-36. PubMed ID: 392367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
